{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:40:17Z","timestamp":1794616817107,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Co-pathology is a common feature of neurodegenerative diseases that complicates diagnosis, treatment and clinical management. However, sensitive, specific and scalable biomarkers for in vivo pathological diagnosis are not available for most neurodegenerative neuropathologies. Here we present Proteomics-based Artificial Intelligence for Dementia Diagnosis (ProtAIDe-Dx), a deep joint-learning model on 17,187 patients and controls (age of 70.3\u2009\u00b1\u200911.5 years, 53.2% female), that uses plasma proteomics to provide simultaneous probabilistic diagnosis across 6 conditions associated with dementia in aging. ProtAIDe-Dx achieves cross-validated balanced classification accuracy of 70\u201395% and area under the curve of &gt;78% across all conditions. The model\u2019s diagnostic probabilities highlighted subgroups of patients with co-pathologies and were associated with pathology-specific biomarkers in an external memory clinic sample, even among individuals without cognitive impairment. Model interpretation revealed a suite of protein networks marking shared and specific biological processes across diseases and identified novel and previously described proteins discriminating each diagnosis. ProtAIDe-Dx significantly improved biomarker-based differential diagnosis in a memory clinic sample, pinpointing proteins leading to diagnostic decisions at an individual level. Together, this work highlights the promise of plasma proteomics to improve patient-level diagnostic workup with a single blood draw.<\/jats:p>","DOI":"10.1038\/s41591-026-04303-y","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:04:52Z","timestamp":1774947892000},"page":"1852-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-4625","authenticated-orcid":false,"given":"Lijun","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Pichet Binette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Hristovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6985-4307","authenticated-orcid":false,"given":"Gabriele","family":"Vilkaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Zendehdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Smets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-6183","authenticated-orcid":false,"given":"Rowan","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-7394","authenticated-orcid":false,"given":"Shinya","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0387-2439","authenticated-orcid":false,"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Krish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-2568","authenticated-orcid":false,"given":"Farhad","family":"Imam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-9874","authenticated-orcid":false,"given":"Danielle","family":"van Westen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Global Neurodegenerative Proteomics Consortium (GNPC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-9940","authenticated-orcid":false,"given":"Jacob W.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"4303_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4303_CR2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. J. Am. Med. Assoc. 330, 512\u2013527 (2023).","journal-title":"J. Am. Med. Assoc."},{"key":"4303_CR3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat. Med. 29, 1437\u20131447 (2023).","journal-title":"Nat. Med."},{"key":"4303_CR4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","volume":"30","author":"A Kirkeby","year":"2023","unstructured":"Kirkeby, A. et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson\u2019s disease, STEM-PD. Cell Stem Cell 30, 1299\u20131314 (2023).","journal-title":"Cell Stem Cell"},{"key":"4303_CR5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","volume":"19","author":"BD Boros","year":"2022","unstructured":"Boros, B. D., Schoch, K. M., Kreple, C. J. & Miller, T. M. Antisense oligonucleotides for the study and treatment of ALS. Neurotherapeutics 19, 1145\u20131158 (2022).","journal-title":"Neurotherapeutics"},{"key":"4303_CR6","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-019-4603-2","volume":"19","author":"A Bernstein","year":"2019","unstructured":"Bernstein, A. et al. Dementia assessment and management in primary care settings: a survey of current provider practices in the United States. BMC Health Serv. Res. 19, 919 (2019).","journal-title":"BMC Health Serv. Res."},{"key":"4303_CR7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist, S. et al. Blood biomarkers to detect Alzheimer disease in primary care and secondary care. J. Am. Med. Assoc. 332, 1245\u20131257 (2024).","journal-title":"J. Am. Med. Assoc."},{"key":"4303_CR8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. J. Am. Med. Assoc. 321, 1286\u20131294 (2019).","journal-title":"J. Am. Med. Assoc."},{"key":"4303_CR9","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/brain\/awad059","volume":"146","author":"JL Robinson","year":"2023","unstructured":"Robinson, J. L. et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain 146, 2557\u20132569 (2023).","journal-title":"Brain"},{"key":"4303_CR10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"D Mehta","year":"2017","unstructured":"Mehta, D., Jackson, R., Paul, G., Shi, J. & Sabbagh, M. Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010\u20132015. Expert Opin. Investig. Drugs 26, 735\u2013739 (2017).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"4303_CR11","doi-asserted-by":"crossref","first-page":"e081990","DOI":"10.1002\/alz.081990","volume":"19","author":"SM Landau","year":"2023","unstructured":"Landau, S. M. et al. Cohort heterogeneity and AD biomarkers in older adults without significant cognitive impairment: a comparison of US POINTER and ADNI. Alzheimers Dement. 19, e081990 (2023).","journal-title":"Alzheimers Dement."},{"key":"4303_CR12","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"4303_CR13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1471-2318-13-137","volume":"13","author":"JE Gaugler","year":"2013","unstructured":"Gaugler, J. E. et al. Characteristics of patients misdiagnosed with Alzheimer\u2019s disease and their medication use: an analysis of the NACC-UDS database. BMC Geriatr. 13, 137 (2013).","journal-title":"BMC Geriatr."},{"key":"4303_CR14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","volume":"10","author":"M Sattlecker","year":"2014","unstructured":"Sattlecker, M. et al. Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 10, 724\u2013734 (2014).","journal-title":"Alzheimers Dement."},{"key":"4303_CR15","doi-asserted-by":"crossref","unstructured":"Shen, X. et al. Nonlinear dynamics of multi-omics profiles during human aging. Nat. Aging 4, 1619\u20131634 (2024).","DOI":"10.1038\/s43587-024-00692-2"},{"key":"4303_CR16","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1021\/acs.jproteome.4c00667","volume":"23","author":"J Candia","year":"2024","unstructured":"Candia, J. et al. Variability of 7K and 11K SomaScan plasma proteomics assays. J. Proteome Res. 23, 5531\u20135539 (2024).","journal-title":"J. Proteome Res."},{"key":"4303_CR17","doi-asserted-by":"crossref","DOI":"10.1186\/s13041-019-0448-1","volume":"12","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg, H. & Burnham, S. C. Blood-based molecular biomarkers for Alzheimer\u2019s disease. Mol. Brain 12, 26 (2019).","journal-title":"Mol. Brain"},{"key":"4303_CR18","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1038\/s41591-025-03834-0","volume":"31","author":"F Imam","year":"2025","unstructured":"Imam, F. et al. The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nat. Med. 31, 2556\u20132566 (2025).","journal-title":"Nat. Med."},{"key":"4303_CR19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.neuron.2013.10.008","volume":"80","author":"C Iadecola","year":"2013","unstructured":"Iadecola, C. The pathobiology of vascular dementia. Neuron 80, 844\u2013866 (2013).","journal-title":"Neuron"},{"key":"4303_CR20","doi-asserted-by":"crossref","unstructured":"Chen, T. & Guestrin, C. XGBoost: a scalable tree boosting system. In Proc. 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 785\u2013794 (ACM, 2016).","DOI":"10.1145\/2939672.2939785"},{"key":"4303_CR21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-024-08328-6","volume":"637","author":"N Hollmann","year":"2025","unstructured":"Hollmann, N. et al. Accurate predictions on small data with a tabular foundation model. Nature 637, 319\u2013326 (2025).","journal-title":"Nature"},{"key":"4303_CR22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1109\/TKDE.2008.239","volume":"21","author":"H He","year":"2009","unstructured":"He, H. & Garcia, E. A. Learning from imbalanced data. IEEE Trans. Knowl. Data Eng. 21, 1263\u20131284 (2009).","journal-title":"IEEE Trans. Knowl. Data Eng."},{"key":"4303_CR23","volume":"12","author":"X Mi","year":"2021","unstructured":"Mi, X., Zou, B., Zou, F. & Hu, J. Permutation-based identification of important biomarkers for complex diseases via machine learning models. Nat. Commun. 12, 3008 (2021).","journal-title":"Nat. Commun."},{"key":"4303_CR24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56293-z","volume":"16","author":"K Bolsewig","year":"2025","unstructured":"Bolsewig, K. et al. Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nat. Commun. 16, 1139 (2025).","journal-title":"Nat. Commun."},{"key":"4303_CR25","doi-asserted-by":"crossref","unstructured":"Dergai, O. et al. Skeletal muscle biomarkers of amyotrophic lateral sclerosis: a large-scale, multi-cohort proteomic study. Ann. Neurol. 99, 393\u2013407 (2025).","DOI":"10.1002\/ana.78046"},{"key":"4303_CR26","unstructured":"Duggan, M. R. et al. OMG! A proteomic determinant of neurodegenerative resiliency. Mol. Neurodegener. 21, 9 (2026)."},{"key":"4303_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack, C. R. Jr et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"4303_CR28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41531-024-00738-7","volume":"10","author":"Y Kuang","year":"2024","unstructured":"Kuang, Y. et al. A skin-specific \u03b1-synuclein seeding amplification assay for diagnosing Parkinson\u2019s disease. npj Parkinsons Dis. 10, 129 (2024).","journal-title":"npj Parkinsons Dis."},{"key":"4303_CR29","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","volume":"30","author":"M Chatterjee","year":"2024","unstructured":"Chatterjee, M. et al. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat. Med. 30, 1771\u20131783 (2024).","journal-title":"Nat. Med."},{"key":"4303_CR30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"4303_CR31","doi-asserted-by":"crossref","unstructured":"Mahmood, F. A benchmarking crisis in biomedical machine learning. Nat. Med. 31, 1060 (2025).","DOI":"10.1038\/s41591-025-03637-3"},{"key":"4303_CR32","doi-asserted-by":"crossref","first-page":"103354","DOI":"10.1016\/j.media.2024.103354","volume":"99","author":"L An","year":"2025","unstructured":"An, L. et al. DeepResBat: deep residual batch harmonization accounting for covariate distribution differences. Med. Image Anal. 99, 103354 (2025).","journal-title":"Med. Image Anal."},{"key":"4303_CR33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-022-04554-y","volume":"604","author":"RaI Bethlehem","year":"2022","unstructured":"Bethlehem, R.aI. et al. Brain charts for the human lifespan. Nature 604, 525\u2013533 (2022).","journal-title":"Nature"},{"key":"4303_CR34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00401-011-0839-6","volume":"122","author":"KA Josephs","year":"2011","unstructured":"Josephs, K. A. et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 122, 137\u2013153 (2011).","journal-title":"Acta Neuropathol."},{"key":"4303_CR35","doi-asserted-by":"crossref","first-page":"e209801","DOI":"10.1212\/WNL.0000000000209801","volume":"103","author":"L Lorenzini","year":"2024","unstructured":"Lorenzini, L. et al. Association of vascular risk factors and cerebrovascular pathology with Alzheimer disease pathologic changes in individuals without dementia. Neurology 103, e209801 (2024).","journal-title":"Neurology"},{"key":"4303_CR36","doi-asserted-by":"publisher","unstructured":"Hristovska, I. et al. Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling. Nat. Aging https:\/\/doi.org\/10.1038\/s43587-026-01081-7 (2026).","DOI":"10.1038\/s43587-026-01081-7"},{"key":"4303_CR37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","volume":"23","author":"A Bradford","year":"2009","unstructured":"Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P. & Singh, H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis. Assoc. Disord. 23, 306\u2013314 (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"4303_CR38","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack, C. R. Jr et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"4303_CR39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois, B. et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484\u2013496 (2021).","journal-title":"Lancet Neurol."},{"key":"4303_CR40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms, B. M. et al. Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat. Aging 4, 33\u201347 (2024).","journal-title":"Nat. Aging"},{"key":"4303_CR41","doi-asserted-by":"crossref","first-page":"eabo6764","DOI":"10.1126\/sciadv.abo6764","volume":"8","author":"Y Iturria-Medina","year":"2022","unstructured":"Iturria-Medina, Y. et al. Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer\u2019s disease progression and heterogeneity. Sci. Adv. 8, eabo6764 (2022).","journal-title":"Sci. Adv."},{"key":"4303_CR42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cell.2024.10.045","volume":"188","author":"Y-T Deng","year":"2025","unstructured":"Deng, Y.-T. et al. Atlas of the plasma proteome in health and disease in 53,026 adults. Cell 188, 253\u2013271 (2025).","journal-title":"Cell"},{"key":"4303_CR43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329\u2013338 (2023).","journal-title":"Nature"},{"key":"4303_CR44","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41593-024-01737-w","volume":"27","author":"A Pichet Binette","year":"2024","unstructured":"Pichet Binette, A. et al. Proteomic changes in Alzheimer\u2019s disease associated with progressive A\u03b2 plaque and tau tangle pathologies. Nat. Neurosci. 27, 1880\u20131891 (2024).","journal-title":"Nat. Neurosci."},{"key":"4303_CR45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamapsychiatry.2020.2549","volume":"78","author":"D Bzdok","year":"2021","unstructured":"Bzdok, D., Varoquaux, G. & Steyerberg, E. W. Prediction, not association, paves the road to precision medicine. JAMA Psychiatry 78, 127\u2013128 (2021).","journal-title":"JAMA Psychiatry"},{"key":"4303_CR46","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.15252\/emmm.201404228","volume":"6","author":"M Pascual-Lucas","year":"2014","unstructured":"Pascual-Lucas, M. et al. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol. Med. 6, 1246\u20131262 (2014).","journal-title":"EMBO Mol. Med."},{"key":"4303_CR47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/brain\/awae229","volume":"148","author":"S Samanta","year":"2025","unstructured":"Samanta, S. et al. Synaptic mitochondria glycation contributes to mitochondrial stress and cognitive dysfunction. Brain 148, 262\u2013275 (2025).","journal-title":"Brain"},{"key":"4303_CR48","doi-asserted-by":"publisher","unstructured":"Oh, H. S.-H. et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer\u2019s disease. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03565-2 (2025).","DOI":"10.1038\/s41591-025-03565-2"},{"key":"4303_CR49","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/brain\/awae032","volume":"147","author":"J Nilsson","year":"2024","unstructured":"Nilsson, J. et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain 147, 2414\u20132427 (2024).","journal-title":"Brain"},{"key":"4303_CR50","doi-asserted-by":"crossref","first-page":"eadf0141","DOI":"10.1126\/scitranslmed.adf0141","volume":"15","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci. Transl. Med. 15, eadf0141 (2023).","journal-title":"Sci. Transl. Med."},{"key":"4303_CR51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","volume":"4","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat. Aging 4, 247\u2013260 (2024).","journal-title":"Nat. Aging"},{"key":"4303_CR52","doi-asserted-by":"crossref","unstructured":"Gan, Y.-H. et al. Large-scale proteomic analyses of incident Parkinson\u2019s disease reveal new pathophysiological insights and potential biomarkers. Nat. Aging 5, 642\u2013657 (2025).","DOI":"10.1038\/s43587-025-00818-0"},{"key":"4303_CR53","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med."},{"key":"4303_CR54","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy, N. R. et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085\u20131095 (2024).","journal-title":"Nat. Med."},{"key":"4303_CR55","doi-asserted-by":"crossref","unstructured":"Halvey, P. et al. Variable blood processing procedures contribute to plasma proteomic variability. Clin. Proteomics 18, 5 (2021).","DOI":"10.1186\/s12014-021-09311-3"},{"key":"4303_CR56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuroimage.2013.10.067","volume":"87","author":"S Haufe","year":"2014","unstructured":"Haufe, S. et al. On the interpretation of weight vectors of linear models in multivariate neuroimaging. Neuroimage 87, 96\u2013110 (2014).","journal-title":"Neuroimage"},{"key":"4303_CR57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. J. Am. Med. Assoc. 324, 772\u2013781 (2020).","journal-title":"J. Am. Med. Assoc."},{"key":"4303_CR58","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamaneurol.2023.1067","volume":"80","author":"A Leuzy","year":"2023","unstructured":"Leuzy, A. et al. Comparison of group-level and individualized brain regions for measuring change in longitudinal tau positron emission tomography in Alzheimer disease. JAMA Neurol. 80, 614\u2013623 (2023).","journal-title":"JAMA Neurol."},{"key":"4303_CR59","volume":"15","author":"L Karlsson","year":"2024","unstructured":"Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. Nat. Commun. 15, 3676 (2024).","journal-title":"Nat. Commun."},{"key":"4303_CR60","unstructured":"Zaj\u0105c, Z. Preparing continuous features for neural networks with GaussRank. FastML https:\/\/fastml.com\/preparing-continuous-features-for-neural-networks-with-rankgauss\/ (2018)."},{"key":"4303_CR61","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41591-024-03118-z","volume":"30","author":"C Xue","year":"2024","unstructured":"Xue, C. et al. AI-based differential diagnosis of dementia etiologies on multimodal data. Nat. Med. 30, 2977\u20132989 (2024).","journal-title":"Nat. Med."},{"key":"4303_CR62","doi-asserted-by":"crossref","unstructured":"Akiba, T., Sano, S., Yanase, T., Ohta, T. & Koyama, M. Optuna: a next-generation hyperparameter optimization framework. In Proc. 25th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining 2623\u20132631 (Association for Computing Machinery, 2019).","DOI":"10.1145\/3292500.3330701"},{"key":"4303_CR63","doi-asserted-by":"crossref","unstructured":"He, T. et al. Meta-matching as a simple framework to translate phenotypic predictive models from big to small data. Nat. Neurosci. 25, 795\u2013804 (2022).","DOI":"10.1038\/s41593-022-01059-9"},{"key":"4303_CR64","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.2017.12126","volume":"318","author":"AC Alba","year":"2017","unstructured":"Alba, A. C. et al. Discrimination and calibration of clinical prediction models: users\u2019 guides to the medical literature. J. Am. Med. Assoc. 318, 1377\u20131384 (2017).","journal-title":"J. Am. Med. Assoc."},{"key":"4303_CR65","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox, C. et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res. 52, D1265\u2013D1275 (2024).","journal-title":"Nucleic Acids Res."},{"key":"4303_CR66","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.cell.2023.08.039","volume":"186","author":"H Mathys","year":"2023","unstructured":"Mathys, H. et al. Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer\u2019s disease pathology. Cell 186, 4365\u20134385 (2023).","journal-title":"Cell"},{"key":"4303_CR67","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41586-021-04369-3","volume":"603","author":"AC Yang","year":"2022","unstructured":"Yang, A. C. et al. A human brain vascular atlas reveals diverse mediators of Alzheimer\u2019s risk. Nature 603, 885\u2013892 (2022).","journal-title":"Nature"},{"key":"4303_CR68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"4303_CR69","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s11357-024-01411-w","volume":"47","author":"R Zhao","year":"2025","unstructured":"Zhao, R. et al. Plasma proteomics-based organ-specific aging for all-cause mortality and cause-specific mortality: a prospective cohort study. Geroscience 47, 1411\u20131423 (2025).","journal-title":"Geroscience"},{"key":"4303_CR70","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Proteomics. tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04303-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04303-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04303-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:03:49Z","timestamp":1779285829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04303-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4303"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04303-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Xu is the cofounder of Andia Health. E.S. has acquired research support (for the institution) from Beckman Coulter, Bristol Myers Squibb, C2N Diagnostics, Eisai, Fujirebio, GE Healthcare and Roche Diagnostics. S.P. has acquired research support (for the institution) from Avid Radiopharmaceuticals and ki elements through ADDF. In the past 3\u2009years, he has received consultancy\/speaker fees from BioArtic, Danaher, Eisai, Eli Lilly, Novo Nordisk, Roche and Sanofi. R.O. is currently a full-time employee of Eli Lilly and Company. His contribution to the work presented in this paper was performed as an employee of Amsterdam University Medical Centers and Lund University. R.O. has received research funding\/support from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer\u2019s fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden, Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer and was an advisory board\/steering committee member for Asceneuron, Biogen, Johnson & Johnson and Bristol Myers Squibb. All the aforementioned has been paid to Amsterdam University Medical Centers and Lund University. N.M.-C. has received consultancy\/speaker fees from Biogen, Eli Lilly, Owkin and Merck. O.H. is an employee of Lund University and Eli Lilly. J.W.V. has received advisory fees from Manifest Technologies within the past 2\u2009years. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}